The gold standard in diabetes modeling and drug discovery involves the use of primary islets of Langerhans—small communities of hormone-producing cells, including insulin-producing beta cells—which are, unfortunately, costly and difficult to obtain. Additionally, primary islets come from donors with different genetic backgrounds, which adds variability to experiments. To address the need for a consistent and reliable source of the beta cells found within these islets, we have developed a standardized differentiation protocol that mimics the typical stages of pancreatic development to create industrial-scale quantities of human hiPS cell-derived beta cells. These beta cells are a powerful alternative to primary islets, as they offer a virtually unlimited source of cells, are easy to culture, and provide reliable and reproducible models for diabetes research and metabolic disease modeling.
Learn more about how our hiPS cell-derived beta cells are suitable for your functional studies, diabetes modeling, and compound screening for insulin secretion and regulation.
Cellartis human iPS cell-derived beta cells for diabetes drug discovery and disease modeling
Studying diabetes and metabolic disorders using hiPSC-derived beta cells.
Takara Bio USA, Inc.
United States/Canada: +1.800.662.2566 • Asia Pacific: +1.650.919.7300 • Europe: +33.(0)1.3904.6880 • Japan: +81.(0)77.565.6999
FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES. © 2023 Takara Bio Inc. All Rights Reserved. All trademarks are the property of Takara Bio Inc. or its affiliate(s) in the U.S. and/or other countries or their respective owners. Certain trademarks may not be registered in all jurisdictions. Additional product, intellectual property, and restricted use information is available at takarabio.com.